{"id":1364,"date":"2026-03-26T08:48:00","date_gmt":"2026-03-26T07:48:00","guid":{"rendered":"https:\/\/www.nutrimedia.info\/?post_type=news&#038;p=1364"},"modified":"2026-03-09T21:48:27","modified_gmt":"2026-03-09T20:48:27","slug":"young-intermittent-fasting-weight-loss","status":"publish","type":"news","link":"https:\/\/www.nutrimedia.info\/en\/news\/jeune-intermittent-cochrane-perte-poids\/","title":{"rendered":"Intermittent Fasting and Cochrane: The Marketing of Fasting Has a Problem (and It's an Opportunity)"},"content":{"rendered":"<p><strong>A Cochrane meta-analysis published in February 2026 has pulled the rug out from under an entire category: intermittent fasting is no better than a conventional diet for weight loss. For manufacturers who have built a narrative around the \u00abmagic\u00bb of meal timing, this is a strong signal. For those who back nutritional quality and evidence, it's an opening.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Intermittent fasting caught up by science (no surprise there)<\/h2>\n\n\n\n<p>The Cochrane Review is the world's leading authority on the synthesis of medical literature. Its verdict on intermittent fasting is unequivocal: <strong>no greater benefit for weight loss compared to a well-managed classical calorie restriction, nor even compared to the absence of a structured programme.<\/strong><\/p>\n\n\n\n<p>The study concerns 22 randomised controlled trials and 1,995 participants. The authors\u00ab conclusion: intermittent fasting \u00bbdoes not appear to help overweight or obese adults lose more weight than conventional dietary advice\".<\/p>\n\n\n\n<p>This outcome does not destroy consumer demand \u2013 people will continue to practice 16:8 and 5:2. <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Le <strong>16:8<\/strong> consists of fasting <strong>16 hours a day<\/strong> and to eat only during a <strong>8-hour window<\/strong> (for example, from 12pm to 8pm).<\/li>\n\n\n\n<li>Le <strong>5:2<\/strong> works on a weekly basis: <strong>5 days of normal eating<\/strong> and <strong>2 day very low-calorie<\/strong> (approx. 500\u2013600 kcal).<\/li>\n<\/ul>\n\n\n\n<p>However, the Cochrane study undermines an implicit promise that had crept into dozens of products, programmes and marketing materials: the idea that the eating window had an intrinsic power beyond just the caloric balance.<\/p>\n\n\n\n<p>For industrialists, the question isn't \u00abis intermittent fasting dead?\u00bb but \u00abwhat is our argument really based on \u2013 and does it hold water?\u00bb<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/www.nutrimedia.info\/wp-content\/uploads\/2026\/03\/Jeune-intermittent-1024x572.jpg\" alt=\"Intermittent fasting and Cochrane: the marketing of fasting has a problem (and it&#039;s an opportunity)\" class=\"wp-image-1352\" srcset=\"https:\/\/www.nutrimedia.info\/wp-content\/uploads\/2026\/03\/Jeune-intermittent-980x547.jpg 980w, https:\/\/www.nutrimedia.info\/wp-content\/uploads\/2026\/03\/Jeune-intermittent-480x268.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Three product territories of intermittent fasting in the spotlight<\/h2>\n\n\n\n<p>An implicit category has been structured around fasting in recent years, without always explicitly claiming it on the packaging:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Meal replacements<\/strong> (shakes, powders, bars) used in meal replacement products, with promises of satiety and high protein content.<\/li>\n\n\n\n<li><strong>Nutrient-dense snacks<\/strong> (high in protein, low in sugar, sometimes fortified with fibre or MCTs) marketed as \u00ab16:8 compatible\u00bb.<\/li>\n\n\n\n<li><strong>Simulated fasting kits\u00ab<\/strong>, multi-day programmes that claim to replicate certain metabolic effects of fasting without complete cessation of eating. This segment is growing, but clinical evidence remains limited.<\/li>\n<\/ul>\n\n\n\n<p>The Cochrane review does not question the relevance of these products. It questions the narrative associated with them when it implies that meal timing does the work instead of nutritional quality and quantity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Nestl\u00e9 already understands (and why it\u2019s instructive)<\/h2>\n\n\n\n<p>In Canada, Nestl\u00e9 Health Science has never prominently featured the term \u00abintermittent fasting\u00bb on its boxes.\u2019<a href=\"https:\/\/www.nestlehealthscience.ca\/fr\/marques\/optifast\" data-type=\"link\" data-id=\"https:\/\/www.nestlehealthscience.ca\/fr\/marques\/optifast\" target=\"_blank\" rel=\"noopener\">Optifast<\/a>. And it's probably a lucid strategic decision.<\/p>\n\n\n\n<p>The group built its credibility on a broader and more defensible territory: evidence-based weight management, with structured programmes, professional support, and products calibrated for nutritional intake. This positioning fares very well against the Cochrane review \u2013 because it did not promise what science cannot deliver.<\/p>\n\n\n\n<p>Even more interesting: as part of his partnership with the Australian Catholic University, Prof. Karagounis explicitly poses the scientific question that will define the next decade \u2013 namely, whether specific dietary components could amplify fasting-induced autophagy. Not as a marketing argument, but as an upstream research programme.<\/p>\n\n\n\n<p>This is the archetype of the smart pivot: investing in the science of tomorrow (metabolism, longevity, autophagy as a research field), while anchoring current products on defensible promises \u2014 nutritional quality, support, clinical evidence \u2014 rather than on the storytelling of meal timing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The real risk: claims that no longer pass the regulatory test<\/h2>\n\n\n\n<p>The Cochrane review sets a precedent that regulators will undoubtedly note. In Europe, the EFSA already strictly regulates health claims related to weight management. Its track record is eloquent: out of 61 opinions published between 2010 and 2020, 55 claims related to\u2019<a href=\"https:\/\/www.nutrimedia.info\/en\/news\/microbiota-bacteria-appetite\/\" data-type=\"news\" data-id=\"1239\">Enjoy your meal<\/a>, satiety and slimming have been rejected.<\/p>\n\n\n\n<p>In concrete terms, the risky formulations are now even more exposed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00abActivate autophagy\u00bb<\/li>\n\n\n\n<li>\u00abMetabolic reset\u00bb<\/li>\n\n\n\n<li>\u00abSuperior to the classic diet\u00bb<\/li>\n<\/ul>\n\n\n\n<p>The defensible formulations remain:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00abEnergy intake control assistance\u00bb<\/li>\n\n\n\n<li>\u00abHigh in protein\u00bb<\/li>\n\n\n\n<li>\u00abWeight management support as part of a calorie-controlled diet\u00bb<\/li>\n<\/ul>\n\n\n\n<p>This is not a question of marketing cynicism. It's a question of compliance and the long-term sustainability of the promise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The post-Cochrane opportunity: nutritional quality returns to its rightful place<\/h2>\n\n\n\n<p>The weight management market isn't going to disappear. What's evolving is the competitive landscape. The manufacturers who will emerge victorious from this reframing are those who:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Investing in measurable nutritional quality \u2013 protein profiles, dietary fibre, micronutrient density \u2013 rather than the timing of meals.<\/li>\n\n\n\n<li>Build framed programmes rather than isolated products \u2013 long-term commitment is built with coaching, digital tools, and follow-up.<\/li>\n\n\n\n<li>Accompanying the revolution <a href=\"https:\/\/www.nutrimedia.info\/en\/news\/glp-1-the-tsunami-sweeping-away-traditional-slimming-diets\/\" data-type=\"news\" data-id=\"547\">GLP-1<\/a> \u2014 the demand for companion products to maintain lean body mass and nutritional coverage in the context of reduced appetite is real and growing. <\/li>\n\n\n\n<li>Document their usage studies \u2014 rather than promising spectacular effects of fasting, show that consumers are actually using the product and achieving their goals.<\/li>\n<\/ol>\n\n\n\n<p><strong>The market isn't disappearing \u2013 it's maturing. And the players who anticipated this maturation by building on a solid foundation have a head start.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FAQ \u2014 Intermittent Fasting Post-Cochrane: What the Pros Are Really Asking<\/h2>\n\n\n\n<p><strong>Is intermittent fasting dead as a marketing lever?<\/strong><\/p>\n\n\n\n<p>No \u2013 but the discourse of being \u00absuperior to classic diets\u00bb is dead. Consumer demand remains strong; it's the implicit promise of an intrinsic advantage of timing that no longer holds. Refocus on practicality, nutritional quality, and support.<\/p>\n\n\n\n<p><strong>Should \u00abfasting friendly\u00bb products be removed from the catalogue?<\/strong><\/p>\n\n\n\n<p>Not necessarily. A product that is high in protein, low in sugar, with a good fibre profile remains relevant for someone practicing 16:8 \u2013 provided you don't promise them that timing does all the work. Nutritional quality sells itself.<\/p>\n\n\n\n<p><strong>What is the concrete risk if one maintains a strong \u00abfasting\u00bb discourse?<\/strong><\/p>\n\n\n\n<p>Two combined risks: regulatory (allegations non-compliant with EFSA if promises overstep into unproven metabolic effects) and reputational (a competitor or journalist citing the Cochrane review against your communications, it will happen).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Video summary<\/h2>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Intermittent fasting: the mega study that changes everything\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/JrYxEiejEH0?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Sources<\/h2>\n\n\n\n<p><strong>1. <\/strong>Garegnani LI et al. \u2014 Cochrane meta-analysis, PMID 41692034, Feb 2026 \u2014 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692034\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/41692034\/<\/a><\/p>\n\n\n\n<p><strong>2. <\/strong>Cochrane.org \u2014 institutional communiqu\u00e9, Feb 2026 \u2014 <a href=\"https:\/\/www.cochrane.org\/about-us\/news\/evidence-behind-intermittent-fasting-weight-loss-fails-match-hype\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.cochrane.org\/about-us\/news\/evidence-behind-intermittent-fasting-weight-loss-fails-match-hype<\/a><\/p>\n\n\n\n<p><strong>3. <\/strong>NutraIngredients \u2014 Nestl\u00e9 Health Science \u00d7 ACU incubator, 18 Feb 2026 \u2014 <a href=\"https:\/\/www.nutraingredients.com\/Article\/2026\/02\/18\/nestle-health-science-australian-catholic-university-set-up-start-up-incubator\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nutraingredients.com\/Article\/2026\/02\/18\/nestle-health-science-australian-catholic-university-set-up-start-up-incubator\/<\/a><\/p>\n\n\n\n<p><strong>4. <\/strong>Nestl\u00e9.com \u2014 ACU partnership, official statement \u2014 <a href=\"https:\/\/www.nestle.com\/about\/research-development\/news\/women-nutrition-health-longevity\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nestle.com\/about\/research-development\/news\/women-nutrition-health-longevity<\/a><\/p>\n\n\n\n<p><strong>5. <\/strong>Nestl\u00e9 Health Science \u2014 Optifast Programme \u2014 <a href=\"https:\/\/www.nestlehealthscience.com\/brands\/optifast\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nestlehealthscience.com\/brands\/optifast<\/a><\/p>\n\n\n\n<p><strong>6. <\/strong>EFSA \u2014 Health claims, Regulation (EC) 1924\/2006 \u2014 <a href=\"https:\/\/www.efsa.europa.eu\/en\/topics\/topic\/health-claims\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.efsa.europa.eu\/en\/topics\/topic\/health-claims<\/a><\/p>\n\n\n\n<p><strong>7. <\/strong>EFSA \u2014 Guidance on weight management and satiety claims \u2014 <a href=\"https:\/\/www.efsa.europa.eu\/en\/applications\/health-claim\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.efsa.europa.eu\/en\/applications\/health-claim<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Are you repositioning your weight management portfolio in light of new scientific data?<\/strong> <br><strong>Do you have a specific question? <\/strong><a href=\"https:\/\/www.nutrimedia.info\/en\/nutrimedia-offers-and-packs\/#chat-avec-nutrimedia\">Talking to the assistant<\/a> <br><strong>\u2192 Need structured support? <\/strong><a href=\"https:\/\/www.nutrimedia.info\/en\/nutrimedia-offers-and-packs\/\">See the offers<\/a> <br><strong>Would you like to discuss it in person? <\/strong><a href=\"https:\/\/calendly.com\/nicolas-nutrimedia\/30min\" target=\"_blank\" rel=\"noopener\">Book a slot (30 min)<\/a><\/td><\/tr><\/tbody><\/table><\/figure>","protected":false},"template":"","meta":{"_acf_changed":true,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false},"class_list":["post-1364","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nutrimedia.info\/en\/wp-json\/wp\/v2\/news\/1364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nutrimedia.info\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.nutrimedia.info\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.nutrimedia.info\/en\/wp-json\/wp\/v2\/media?parent=1364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}